David Fiorentino, MD, PhD

Publications

• Validation of the ICD-9-CM code for systemic sclerosis using updated ACR/EULAR classification criteria
  VALENZUELA, A., Yaqub, A., Fiorentino, D., Krishnan, E., & Chung, L. (2015). Validation of the ICD-9-CM code for systemic sclerosis using updated ACR/EULAR classification criteria. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 44(3), 253-255.
• Cutaneous Ulceration in Dermatomyositis: Association With Anti-Melanoma Differentiation-Associated Gene 5 Antibodies and Interstitial Lung Disease
  Narang, N. S., Casciola-Rosen, L., Li, S., Chung, L., & Fiorentino, D. F. (2015). Cutaneous Ulceration in Dermatomyositis: Association With Anti-Melanoma Differentiation-Associated Gene 5 Antibodies and Interstitial Lung Disease. ARTHRITIS CARE & RESEARCH, 67(5), 667-672.
• Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
  Chakravarty, E. F., Martyanov, V., Fiorentino, D., Wood, T. A., Haddon, D. J., & Chung, L. (2015). Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis research & therapy, 17, 159-?.
• Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: Results of a prospective pilot study. Chung, L., Ball, K., Yaqub, A., Lingala, B., & Fiorentino, D. (2014). Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: Results of a prospective pilot study. Journal of the American Academy of Dermatology, 71(2), 400-401.
  
• Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. Valenzuela, A., Chung, L., Casciola-Rosen, L., & Fiorentino, D. (2014). Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA dermatology, 150(7), 724-729.
  
• Atherosclerotic Cardiovascular Disease in Hospitalized Patients With Systemic Sclerosis: Higher Mortality Than Patients With Lupus and Rheumatoid Arthritis Dave, A. J., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2014). Atherosclerotic Cardiovascular Disease in Hospitalized Patients With Systemic Sclerosis: Higher Mortality Than Patients With Lupus and Rheumatoid Arthritis. ARTHRITIS CARE & RESEARCH, 66(2), 323-327.
  
• A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-a monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Higgs, B. W., Zhu, W., Morehouse, C., White, W. I., Brohawn, P., & Yao, Y. (2014). A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-a monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Annals of the rheumatic diseases, 73(1), 256-262.
  
• The plasma cell signature in autoimmune disease. Streicher, K., Morehouse, C. A., Groves, C. J., Rajan, B., Pilataxi, F., & Ranade, K. (2014). The plasma cell signature in autoimmune disease. Arthritis & rheumatology , 66(1), 173-184.
  
• Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?. Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., & Casciola-Rosen, L. (2013). Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1?. Arthritis and rheumatism, 65(11), 2954-2962.
  
• Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?. Fiorentino, D. F., Chung, L. S., Christopher-Stine, L., Zaba, L., Li, S., & Casciola-Rosen, L. (2013). Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1?. Arthritis and rheumatism, 65(11), 2954-2962.
  
• Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study Strand, V., Fiorentino, D., Hu, Cc., Day, R. M., Stevens, R. M., & Papp, K. A. (2013). Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. HEALTH AND QUALITY OF LIFE OUTCOMES, 11.
  
• Localized Cutaneous Fibrosing Disorders Yaqub, A., Chung, L., Rieger, K. E., & Fiorentino, D. F. (2013). Localized Cutaneous Fibrosing Disorders. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 39(2), 347-?.
  
• Localized cutaneous fibrosing disorders. Yaqub, A., Chung, L., Rieger, K. E., & Fiorentino, D. F. (2013). Localized cutaneous fibrosing disorders. Rheumatic diseases clinics of North America, 39(2), 347-364.
  
• Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases de Souza, A., Ali-Shaw, T., Reddy, S. M., Fiorentino, D., & Strober, B. E. (2013). Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. BRITISH JOURNAL OF DERMATOLOGY, 168(1), 210-212.
  
• Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Linos, E., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2013). Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis research & therapy, 15(1), R7-?.
  
• Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey Linos, E., Fiorentino, D., Lingala, B., Krishnan, E., & Chung, L. (2013). Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. ARTHRITIS RESEARCH & THERAPY, 15(1).
  
• Genomic signatures characterize leukocyte infiltration in myositis muscles Zhu, W., Streicher, K., Shen, N., Higgs, B. W., Morehouse, C., & Yao, Y. (2012). Genomic signatures characterize leukocyte infiltration in myositis muscles. BMC MEDICAL GENOMICS, 5.
  
• Skin disease in dermatomyositis Zaba, L. C., & Fiorentino, D. F. (2012). Skin disease in dermatomyositis. CURRENT OPINION IN RHEUMATOLOGY, 24(6), 597-601.
  
• Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients. Fiorentino, D., Chung, L., Zaba, L., Lingala, B., Rosen, A., & Casciola-Rosen, L. (2012). Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients. ARTHRITIS AND RHEUMATISM, 64(10), S828-S828.
  
• Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., & Mosmann, T. R. (2012). Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI. JOURNAL OF IMMUNOLOGY, 189(5), 1230-1234.
  
• Clinical presentation and evaluation of dermatomyositis. Marvi, U., Chung, L., & Fiorentino, D. F. (2012). Clinical presentation and evaluation of dermatomyositis. Indian journal of dermatology, 57(5), 375-381.
  
• Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab Sarin, K. Y., & Fiorentino, D. (2012). Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab. ARCHIVES OF DERMATOLOGY, 148(9), 990-992.
  
• Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment Strand, V., Sharp, V., Koenig, A. S., Park, G., Shi, Y., & Fiorentino, D. (2012). Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. ANNALS OF THE RHEUMATIC DISEASES, 71(7), 1143-1150.
  
• A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies Report of 2 Cases and Review of the Literature Chaisson, N. F., Paik, J., Orbai, A.-M., Casciola-Rosen, L., Fiorentino, D., & Rosen, A. (2012). A Novel Dermato-Pulmonary Syndrome Associated With MDA-5 Antibodies Report of 2 Cases and Review of the Literature. MEDICINE, 91(4), 220-228.
  
• Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection Fiorentino, D., & Casciola-Rosen, L. (2012). Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. ARTHRITIS AND RHEUMATISM, 64(2), 346-349.
  
• Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients Higgs, B. W., Zhu, W., Richman, L., Fiorentino, D. F., Greenberg, S. A., & Yao, Y. (2012). Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 15(1), 25-35.
  
• Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases Wong, D., Kea, B., Pesich, R., Higgs, B. W., Zhu, W., & Fiorentino, D. (2012). Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases. PLOS ONE, 7(1).
  
• Consensus Guidelines for the Management of Plaque Psoriasis Hsu, S., Papp, K. A., Lebwohl, M. G., Bagel, J., Blauvelt, A., & Bebo, B. F. (2012). Consensus Guidelines for the Management of Plaque Psoriasis. ARCHIVES OF DERMATOLOGY, 148(1), 95-102.
  
• Quality of life in dermatomyositis Goreshi, R., Chock, M., Foering, K., Feng, R., Okawa, J., & Werth, V. (2011). Quality of life in dermatomyositis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(6), 1107-1116.
  
• Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway Higgs, B. W., Liu, Z., White, B., Zhu, W., White, W. I., & Yao, Y. (2011). Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. ANNALS OF THE RHEUMATIC DISEASES, 70(11), 2029-2036.
  
• Tyrosine kinases in inflammatory dermatologic disease Paniagua, R. T., Fiorentino, D. F., Chung, L., & Robinson, W. H. (2011). Tyrosine kinases in inflammatory dermatologic disease. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(2), 389-403.
  
• The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study Fiorentino, D., Chung, L., Zwerner, J., Rosen, A., & Casciola-Rosen, L. (2011). The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 65(1), 25-34.
  
• Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon Kao, L., Chung, L., & Fiorentino, D. F. (2011). Pathogenesis of Dermatomyositis: Role of Cytokines and Interferon. CURRENT RHEUMATOLOGY REPORTS, 13(3), 225-232.
  
• Prevalence of Children with Severe Fetal Alcohol Spectrum Disorders in Communities Near Rome, Italy: New Estimated Rates Are Higher than Previous Estimates May, P. A., Fiorentino, D., Coriale, G., Kalberg, W. O., Hoyme, H. E., & Ceccanti, M. (2011). Prevalence of Children with Severe Fetal Alcohol Spectrum Disorders in Communities Near Rome, Italy: New Estimated Rates Are Higher than Previous Estimates. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 8(6), 2331-2351.
  
• The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes Fiorentino, D. F., Chen, R. O., STEWART, D. B., Brown, K. K., & Sundram, U. N. (2011). The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes. BRITISH JOURNAL OF DERMATOLOGY, 164(5), 996-1003.
  
• International consensus for a definition of disease flare in lupus Ruperto, N., HANRAHAN, L. M., Alarcon, G. S., Belmont, H. M., Brey, R. L., & Merrill, J. T. (2011). International consensus for a definition of disease flare in lupus. LUPUS, 20(5), 453-462.
  
• A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris Fiorentino, D. F., Garcia, M. S., Rehmus, W., & Kimball, A. B. (2011). A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris. ARCHIVES OF DERMATOLOGY, 147(1), 117-118.
  
• Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. Arefiev, K., Fiorentino, D. F., & Chung, L. (2011). Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. International journal of rheumatology, 2011, 201787-?.
  
• Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument Yassaee, M., Fiorentino, D., Okawa, J., Taylor, L., Coley, C., & Werth, V. P. (2010). Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. BRITISH JOURNAL OF DERMATOLOGY, 162(3), 669-673.
  
• Conditioned Pharmacotherapeutic Effects: A Preliminary Study Ader, R., Mercurio, M. G., Walton, J., James, D., Davis, M., & Fiorentino, D. (2010). Conditioned Pharmacotherapeutic Effects: A Preliminary Study. PSYCHOSOMATIC MEDICINE, 72(2), 192-197.
  
• Treatment recommendations for psoriatic arthritis Ritchlin, C. T., Kavanaugh, A., Gladman, D. D., Mease, P. J., Helliwell, P., & Taylor, W. J. (2009). Treatment recommendations for psoriatic arthritis. ANNALS OF THE RHEUMATIC DISEASES, 68(9), 1387-1394.
  
• MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial Chung, L., Shapiro, L., Fiorentino, D., Baron, M., Shanahan, J., & Wigley, F. M. (2009). MQX-503, a Novel Formulation of Nitroglycerin, Improves the Severity of Raynaud's Phenomenon A Randomized, Controlled Trial. ARTHRITIS AND RHEUMATISM, 60(3), 870-877.
  
• Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis Chung, L., Fiorentino, D. F., Benbarak, M. J., Adler, A. S., Mariano, M. M., & Robinson, W. H. (2009). Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis. ARTHRITIS AND RHEUMATISM, 60(2), 584-591.
  
• Imatinib in the Treatment of Nephrogenic Systemic Fibrosis Chandran, S., Petersen, J., Jacobs, C., Forentino, D., Doeden, K., & Lafayette, R. A. (2009). Imatinib in the Treatment of Nephrogenic Systemic Fibrosis. AMERICAN JOURNAL OF KIDNEY DISEASES, 53(1), 129-132.
  
• Type I Interferon in the Induction or Exacerbation of Dermatomyositis What This Observation Tells Us About the Naturally Occurring Disease Fiorentino, D. F. (2008). Type I Interferon in the Induction or Exacerbation of Dermatomyositis What This Observation Tells Us About the Naturally Occurring Disease. ARCHIVES OF DERMATOLOGY, 144(10), 1379-1382.
  
• Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis Klein, R. Q., Bangert, C. A., Costner, M., Connolly, M. K., Tanikawa, A., & Werth, V. P. (2008). Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. BRITISH JOURNAL OF DERMATOLOGY, 159(4), 887-894.
  
• Molecular framework for response to imatinib mesylate in systemic sclerosis Chung, L., Fiorentino, D. F., Benbarak, M. J., Adler, A. S., Mariano, M. M., & Robinson, W. H. (2008). Molecular framework for response to imatinib mesylate in systemic sclerosis. ARTHRITIS AND RHEUMATISM, 58(9), S819-S820.
  
• Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis Hantash, B. M., Chiang, D., Kohler, S., & Fiorentino, D. (2008). Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 58(4), 661-664.
  
• Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? Fleming, J. N., Nash, R. A., McLeod, D. O., Fiorentino, D. F., Shulman, H. M., & Schwartz, S. M. (2008). Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?. PLOS ONE, 3(1).
  
• Localized scleroderma and systemic sclerosis: Is there a connection? Gupta, R. A., & Fiorentino, D. (2007). Localized scleroderma and systemic sclerosis: Is there a connection?. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 21(6), 1025-1036.
  
• Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis Richmond, H., Zwerner, J., Kim, Y., & Fiorentino, D. (2007). Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis. ARCHIVES OF DERMATOLOGY, 143(8), 1025-1030.
  
• Mycophenolate mofetil Zwerner, J., & Fiorentino, D. (2007). Mycophenolate mofetil. DERMATOLOGIC THERAPY, 20(4), 229-238.
  
• A pilot trial of rituximab in the treatment of patients with dermatomyositis Chung, L., Genovese, M. C., & Fiorentino, D. F. (2007). A pilot trial of rituximab in the treatment of patients with dermatomyositis. ARCHIVES OF DERMATOLOGY, 143(6), 763-767.
  
• Comparison of the reliability & validity of outcome instruments for cutaneous dermatomyositis Quain, R. D., Bangert, C. C., Costner, M., Connolly, M. K., Dugan, E., & Werth, V. P. (2007). Comparison of the reliability & validity of outcome instruments for cutaneous dermatomyositis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 127, S59-S59.
  
• Update on cutaneous vasculitis Grzeszkiewicz, T. M., & Fiorentino, D. F. (2006). Update on cutaneous vasculitis. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 25(4), 221-225.
  
• Successful use of rituximab for cutaneous vasculitis Chung, L., Funke, A. A., Chakravarty, E. F., Callen, J. P., & Fiorentino, D. F. (2006). Successful use of rituximab for cutaneous vasculitis. ARCHIVES OF DERMATOLOGY, 142(11), 1407-1410.
  
• Systemic and locatized scleroderma Chung, L., Lin, J., Furst, D. E., & Fiorentino, D. (2006). Systemic and locatized scleroderma. CLINICS IN DERMATOLOGY, 24(5), 374-392.
  
• Epidemiology of FASD in a province in Italy: Prevalence and characteristics of children in a random sample of schools May, P. A., Fiorentino, D., Gossage, J. P., Kalberg, W. O., Hoyme, H. E., & Ceccanti, M. (2006). Epidemiology of FASD in a province in Italy: Prevalence and characteristics of children in a random sample of schools. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 30(9), 1562-1575.
  
• A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Chung, L., & Fiorentino, D. (2006). A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 54(5), 880-882.
  
• Digital ulcers in patients with systemic sclerosis Chung, L., & Fiorentino, D. (2006). Digital ulcers in patients with systemic sclerosis. AUTOIMMUNITY REVIEWS, 5(2), 125-128.
  
• Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil Hantash, B., & Fiorentino, D. (2006). Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. ARCHIVES OF DERMATOLOGY, 142(1), 109-110.
  
• Muir-Torre syndrome: Confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions Fiorentino, D. F., Nguyen, J. C., Egbert, B. M., & Swetter, S. M. (2004). Muir-Torre syndrome: Confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 50(3), 476-478.
  
• Cutaneous vasculitis Fiorentino, D. F. (2003). Cutaneous vasculitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 48(3), 311-340.
  
• Characterization of Saccharomyces cerevisiae dna2 mutants suggests a role for the helicase late in S phase Fiorentino, D. F., & Crabtree, G. R. (1997). Characterization of Saccharomyces cerevisiae dna2 mutants suggests a role for the helicase late in S phase. MOLECULAR BIOLOGY OF THE CELL, 8(12), 2519-2537.
  
• The mechanism of action of cyclosporin A and FK506 Ho, S., Clipstone, N., Timmermann, L., Northrop, J., Graef, I., & Crabtree, G. R. (1996). The mechanism of action of cyclosporin A and FK506. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 80(3), S40-S45.
  
• TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN Zheng, X. F., Fiorentino, D., Chen, J., Crabtree, G. R., & Schreiber, S. L. (1995). TOR KINASE DOMAINS ARE REQUIRED FOR 2 DISTINCT FUNCTIONS, ONLY ONE OF WHICH IS INHIBITED BY RAPAMYCIN. CELL, 82(1), 121-130.
  
• IMMUNOPHILINS INTERACT WITH CALCINEURIN IN THE ABSENCE OF EXOGENOUS IMMUNOSUPPRESSIVE LIGANDS Cardenas, M. E., Hemenway, C., Muir, R. S., Ye, R., Fiorentino, D., & Heitman, J. (1994). IMMUNOPHILINS INTERACT WITH CALCINEURIN IN THE ABSENCE OF EXOGENOUS IMMUNOSUPPRESSIVE LIGANDS. EMBO JOURNAL, 13(24), 5944-5957.
  
• MOLECULAR ANALYSIS OF THE INTERACTION OF CALCINEURIN WITH DRUG-IMMUNOPHILIN COMPLEXES Clipstone, N. A., Fiorentino, D. F., & Crabtree, G. R. (1994). MOLECULAR ANALYSIS OF THE INTERACTION OF CALCINEURIN WITH DRUG-IMMUNOPHILIN COMPLEXES. JOURNAL OF BIOLOGICAL CHEMISTRY, 269(42), 26431-26437.
  
• RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE Kuo, C. J., Chung, J. K., Fiorentino, D. F., Flanagan, W. M., Blenis, J., & Crabtree, G. R. (1992). RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE. NATURE, 358(6381), 70-73.
  
• IL-10 INHIBITS CYTOKINE PRODUCTION BY ACTIVATED MACROPHAGES Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., & OGARRA, A. (1991). IL-10 INHIBITS CYTOKINE PRODUCTION BY ACTIVATED MACROPHAGES. JOURNAL OF IMMUNOLOGY, 147(11), 3815-3822.
  
• PRODUCTION OF IL-10 BY CD4+ LYMPHOCYTES-T CORRELATES WITH DOWN-REGULATION OF TH1 CYTOKINE SYNTHESIS IN HELMINTH INFECTION Sher, A., Fiorentino, D., Caspar, P., Pearce, E., & Mosmann, T. (1991). PRODUCTION OF IL-10 BY CD4+ LYMPHOCYTES-T CORRELATES WITH DOWN-REGULATION OF TH1 CYTOKINE SYNTHESIS IN HELMINTH INFECTION. JOURNAL OF IMMUNOLOGY, 147(8), 2713-2716.
  
• DIVERSITY OF CYTOKINE SYNTHESIS AND FUNCTION OF MOUSE CD4+ T-CELLS Mosmann, T. R., SCHUMACHER, J. H., STREET, N. F., Budd, R., OGARRA, A., & Fiorentino, D. F. (1991). DIVERSITY OF CYTOKINE SYNTHESIS AND FUNCTION OF MOUSE CD4+ T-CELLS. IMMUNOLOGICAL REVIEWS, 123, 209-229.
  
• IL-10 ACTS ON THE ANTIGEN-PRESENTING CELL TO INHIBIT CYTOKINE PRODUCTION BY TH1 CELLS Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., & OGARRA, A. (1991). IL-10 ACTS ON THE ANTIGEN-PRESENTING CELL TO INHIBIT CYTOKINE PRODUCTION BY TH1 CELLS. JOURNAL OF IMMUNOLOGY, 146(10), 3444-3451.
  
• ISOLATION AND EXPRESSION OF HUMAN CYTOKINE SYNTHESIS INHIBITORY FACTOR CDNA CLONES - HOMOLOGY TO EPSTEIN-BARR-VIRUS OPEN READING FRAME BCRFI Vieira, P., DEWAALMALEFYT, R., Dang, M. N., Johnson, K. E., Kastelein, R., & Moore, K. W. (1991). ISOLATION AND EXPRESSION OF HUMAN CYTOKINE SYNTHESIS INHIBITORY FACTOR CDNA CLONES - HOMOLOGY TO EPSTEIN-BARR-VIRUS OPEN READING FRAME BCRFI. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 88(4), 1172-1176.
  
• EXPRESSION OF INTERLEUKIN-10 ACTIVITY BY EPSTEIN-BARR-VIRUS PROTEIN BCRF1 Hsu, D. H., Malefyt, R. D., Fiorentino, D. F., Dang, M. N., Vieira, P., & Moore, K. W. (1990). EXPRESSION OF INTERLEUKIN-10 ACTIVITY BY EPSTEIN-BARR-VIRUS PROTEIN BCRF1. SCIENCE, 250(4982), 830-832.
  
• ISOLATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR IL-4, IL-5, IL-6, AND A NEW TH2-SPECIFIC CYTOKINE (IL-10), CYTOKINE SYNTHESIS INHIBITORY FACTOR, BY USING A SOLID-PHASE RADIOIMMUNOADSORBENT ASSAY Mosmann, T. R., SCHUMACHER, J. H., Fiorentino, D. F., LEVERAH, J., Moore, K. W., & Bond, M. W. (1990). ISOLATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR IL-4, IL-5, IL-6, AND A NEW TH2-SPECIFIC CYTOKINE (IL-10), CYTOKINE SYNTHESIS INHIBITORY FACTOR, BY USING A SOLID-PHASE RADIOIMMUNOADSORBENT ASSAY. JOURNAL OF IMMUNOLOGY, 145(9), 2938-2945.
  
• HOMOLOGY OF CYTOKINE SYNTHESIS INHIBITORY FACTOR (IL-10) TO THE EPSTEIN-BARR-VIRUS GENE BCRFI Moore, K. W., Vieira, P., Fiorentino, D. F., TROUNSTINE, M. L., Khan, T. A., & Mosmann, T. R. (1990). HOMOLOGY OF CYTOKINE SYNTHESIS INHIBITORY FACTOR (IL-10) TO THE EPSTEIN-BARR-VIRUS GENE BCRFI. SCIENCE, 248(4960), 1230-1234.
  
• HETEROGENEITY OF MOUSE HELPER T-CELLS - EVIDENCE FROM BULK CULTURES AND LIMITING DILUTION CLONING FOR PRECURSORS OF TH1 AND TH2 CELLS Street, N. E., SCHUMACHER, J. H., Fong, T. At., Bass, H., Fiorentino, D. F., & Mosmann, T. R. (1990). HETEROGENEITY OF MOUSE HELPER T-CELLS - EVIDENCE FROM BULK CULTURES AND LIMITING DILUTION CLONING FOR PRECURSORS OF TH1 AND TH2 CELLS. JOURNAL OF IMMUNOLOGY, 144(5), 1629-1639.
  
• 2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989). 2 TYPES OF MOUSE T-HELPER CELL .4. TH2 CLONES SECRETE A FACTOR THAT INHIBITS CYTOKINE PRODUCTION BY TH1 CLONES. JOURNAL OF EXPERIMENTAL MEDICINE, 170(6), 2081-2095.
  
• HETEROGENEITY OF MOUSE HELPER T-CELLS AND CROSS-REGULATION OF TH1 AND TH2 CLONES Mosmann, T. R., Street, N. E., Fiorentino, D. F., Bond, M. W., Fong, T. At., & Moore, K. W. (1989). HETEROGENEITY OF MOUSE HELPER T-CELLS AND CROSS-REGULATION OF TH1 AND TH2 CLONES. SPRINGER-VERLAG BERLIN.